The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes i was lucky to be in at 3 pence, but also bought from memory at 4,5,6, 10 & 12 pence. Think im averaging around 5 pence ish.
The potential value of nxp002 is just unreal aim. And while i too could kick myself for not top slicing a little i am just happy to sit and wait and keep an eye out for updates.
Its been said before but once trials start on nxp002 the anticipation should drive this through the roof. Any updates on other deals like ebers will add to the upturn. Just got to be patient and am happy to hold through the highs and lows.
Cdub, it really has been brutal. Still havent sold a single share (more fool me) but thats life and i am still in profit here. This has the hallmarks of a very decent company and i stand to make a hell of a lot of money long term if just half the pipeline goes to plan. So although ive not traded the highs and lows i ll still make alot of money. I can live with that.
The reality is we need the 500k milestone payment from china asap. I dont think the company have enough cash to commence a human pk study with nxp002 so if they have sorted a delivery method out it may be holding progress up but who knows?
I think in previous statements the company has said a total of around 560k will see nxp002 through that study so once payment is received it will not only prove nsb/yatai are keeping to their side of the deal but also hopefully kick start other activities that may have been put on hold.
Cheers mars/jay. I do understand theres a natural progression for nxp001 moving over to yatai and their greater resources. Just thinking out loud really. That 500k was triggered along time ago now but Dan said the payment was days away so i expect things to pick up from here when its in the bank.
I dont understand why we would be moved from nsb over to yatai unless they want a piece of nxp002? At some point we are going to complete final preperations for method of drug delivery then its into more trials.
Wonder if the move over to yatai is just in readiness for progression of nxp002? I also think 2.5 million owed is a great bargaining chip to have if yatai ask nuformix for outlicensing talks on nxp002. Maybe am being too cynical
Thanks for that aim. Just to summarise the figures mentioned in his video, which were highlighted to justin via email by the nufornix ceo dan gooding....
Tecfidera bought for a fee of 510 million dollars (for a partial buy in!) and a later fee of 761 million dollars. Rhofade was acquired for 275 million dollars.
Huge figures and a big call to highlight out licensing deals of this magnitude. But dan has continually mentioned he wants to emulate what has happened with tecfidera in his interviews. Hes never highlighted figures until now. So i guess he must be confident of achieving something near to these.
Yes jayblu, funding in THIS instance is an extremely good thing. We arent funding because the companies going bust and we need more money for directors salaries like most of the dross out there.
We may need funding in the future if trials on our biggest assets go extremely well and we need to fund bigger patient studies which will in turn deliver huge benefit to shareholders.
We need to think when funding is mentioned about why its needed. In Nuformix case its a positive thing. In other death spiral companies its a different ball game.
Nuformix fully funded for 2019, hopefully will never need funding if revenues keep coming in quickly enough, but if we do its for the good of the company and shareholders.
Had a chat with sp'ex who have no orders to fill so are not selling at the moment. Have nfx timed this rns with the last few remaining shares of the 100k seller? If so this will erupt... Just sold the last of my FARN shares at a small loss and bought more in here. Fingers crossed
So after a quick scan through we have an ebers update of sorts, first being we have received already an upfront payment from the deal....
"The deal has brought in upfront revenue, with further near-term payments driven by patent filings and pre-clinical outcomes"
Mentions also that we ll get future payments linked to patents, which is then backed up by this statement .....
"The Group is pleased to announce that it has discovered new cocrystal drug forms for molecules of therapeutic and commercial interest."
Thats a really huge bit of news, presumes it links to ebers.
Also states once more we are fully funded through 2019. Will be very interesting to listen to the vox interview later.
Hopefully so! Really interested to get more info on that as cant find anything on it so will have to wait. Im sure a more detailed review of nxp001 results will be due to dan and co anytime now so am hopeful of an update cone the end of july
Dan has previously stated that nxp001 alone has the potential of bringing in upto 200 million per year for CINV. So potentially upto 20 million a year revenue for NFX. The company dont announce this as it all depends on how well each outlicensing partner markets and distributes nxp001. Rest assured they're the figures the boffins at nuformix hope to achieve from nxp001 for CINV. But as we cant put a realistic figure on this right now or ebers or nxp002 the company will be hugely undervalued for a while yet.
The following is an extract from nuformix presentation on their main site. It explains the basics of what they are trying to achieve with nxp002. Theres lots of instances of companies over the years trying and failing to do what nfx is doing right now. Including an aussie company bought out for 80 mill at a very early stage of expensive clinical trials for their work with a possible fibrosis drug that was eventually discontinued. Large pharmas have conducted trials with tranilast and abandoned also. Nuformix is using cocrystal tech to get round these issues and has proved it with nxp001 already. This is off their website........
"NXP002 is an approved drug in Japan, China & Korea with no existing patent protection
• Strong safety record in thousands of patients including paediatrics
• The mechanism of NXP002 targets a pathway essential to the formation of all types of fibrosis
- Nuformix has gained leading academic and KOL validation for NX002’s potential in all fibrotic diseases
- In-vitro data demonstrates NXP002’s vast superiority versus marketed IPF treatments in inhibiting key stages of the fibrotic process
• The current marketed drug form cannot exploit it’s vast anti-fibrotic potential
- Very poor oral bioavailability and high oral variability (x10)
- Attempts with numerous technologies have failed to overcome oral delivery issues
• Nuformix’s patented NXP002 cocrystal enables consistent, efficacious oral delivery
- In-vitro & in-vivo data demonstrates that its patented forms of NXP002 enable delivery where all other approaches have failed
- Opens up future use in all fibrotic conditions
• US & European approval provides up to 10 years additional market exclusivity protection
Nuformix will demonstrate via a human PK study that it can deliver NXP002 in a standard
oral formulation optimised for the chronic needs of treating fibrotic diseases"
Slightly disappointing week to be honest, was hoping for some news but here we all are. I still havent sold a bean as i hope we are due very shortly some news on funding and inturn nxp002 update.
If anyone is getting impatient then read up on tranilast. Read up on what this drug can potentially treat and why it hasnt quite achieved its full potential just yet. The info has been out there for months and months. Its why i have put 90% of my entire life savings into a pharma company. It will take an hour or 2 but will make you feel much better about the few % we've slipped each day.
The tech is now proven so we just need to repeat the process of nxp001. Its a little more time consuming and costly but it will reward many many times that of nxp001.
Incidentally tranilast is only approved in japan and south korea.
Nxp002
Anyone frustrated with no recent news just read december 3rd RNS on results pitting nxp002 against Esbriet....which is a blockbuster drug. Esbriet has many drawbacks inc huge costs, severe side effects etc. So we already have 2 ways in which we have big upside. Then in pre clinical we outperformed it (dec 3rd RNS)
We have patents on various forms of tranilast to treat lung fibrosis (amongst many other conditions) Tranilast is really insoluble though...so nuformix do their co crystal thing and instead of needing a 100mg dose of tranilast we can achieve better results with 1 or 2 mg doses which inturn has potential to really reduce side effects. They then improve the drug in all sorts of other ways which is way over my head.
The results of pre clinical trials via decembers rns were incredible, the importance of which have been lost on most people over the course of time. dan has already said we could be testing 002 in patients early next year.
I know its boring watching the price drift but all the clues are there. And now we have the added kicker of 001 proving up the tech. This is a huge play on its own. Never mind all the ebers stuff jay mentioned earlier. Tranilast can potentially treat other fibrotic conditions and many other diseases aswell.
This price isnt going to drift for much longer IMO
Mars, it appears theyre on the brink of something special reading that article and listening to what Dan has already said. Hes already said they have made great progress on Cannabinoids but how that breaks down for shareholders is anyones guess.
Just checked back and cottoner spotted the article last thursday.....the last time dan decided to spread the word in the cambridge indi the ebers deal was released via rns the following tuesday. Whats the odds he decides to follow the same pattern?
This article may have already been posted but an interesting read about our progression into cannabinoids. Apparently nfx have been developing this for 2 years .... I wonder what they've developed so far to earn a 51 million deal. Cant wait to find out.
https://www.cambridgeindependent.co.uk/news/cannabis-benefits-mount-up-for-cambridge-science-9074755/
Aim, its clear from his rambling posts hes had 1 to many this evening. I was trying to be nice earlier but maybe should have gone down your route. Well said and lets hope too many dont fall for his double bluff.